Members |
targetComponentId |
Drug groups primarily affecting autonomic nervous system adverse reaction |
Adverse reaction to drug |
Drug groups primarily affecting cardiovascular system adverse reaction |
Adverse reaction to drug |
Drug groups primarily affecting central nervous system adverse reaction |
Adverse reaction to drug |
Drug groups primarily affecting gastrointestinal system adverse reaction |
Adverse reaction to drug |
Drug groups primarily affecting musculoskeletal system adverse reaction |
Adverse reaction to drug |
Drug groups primarily affecting respiratory system adverse reaction |
Adverse reaction to drug |
Drug groups primarily affecting the autonomic nervous system |
Product containing autonomic agent (product) |
Drug induced rash (& ingestion dermatitis) |
Dermatitis caused by substance taken via oral route (disorder) |
Drug level in urine specimen above therapeutic range |
Urine substance level above reference range (finding) |
Drug ointment, 0,025% |
Ointment |
Drug ointment, 0,05% |
Ointment |
Drug ointment, 0,1% |
Ointment |
Drug ointment, 0,2% |
Ointment |
Drug ointment, 0,25% |
Ointment |
Drug ointment, 1% |
Ointment |
Drug ointment, 2,5% |
Ointment |
Drug reaction - CNS drug |
Adverse reaction to drug |
Drug reaction - CNS drug |
Adverse reaction to drug |
Drug reaction - CNS drug NOS |
Adverse reaction to drug |
Drug reaction - CNS drug NOS |
Adverse reaction to drug |
Drug specific allergen extract |
Pharmaceutical / biologic product (product) |
Drug therapy status |
Drug therapy with explicit context |
Drug withdrawal |
Substance withdrawal |
Drug withdrawal seizure |
Seizure co-occurrent and due to substance withdrawal |
Drug withdrawal syndrome |
Substance withdrawal |
Drug withdrawal syndrome |
Substance withdrawal |
Drug, medicament or biological substance |
Drug or medicament (substance) |
Drug, medicament, or biological substance in urine above reference range |
Urine substance level above reference range (finding) |
Drug-induced impotence |
Erectile dysfunction caused by drug |
Drug-induced nephrogenic diabetes insipidus |
Acquired vasopressin resistance |
Drug-related disorder |
Disease |
Drugs in urine abnormal [D] |
Substance in urine detected by screening method (finding) |
Drugs used in hyperuricemia |
Uricosuric agent |
Drugs used in metabolic disorders |
Medicinal product categorised by therapeutic role |
Drusen |
Hyaline body |
Duct ectasia |
Dilatation |
Ductal carcinoma in situ - category |
Non-infiltrating intraductal carcinoma |
Dukes-Filatow disease |
Rubeola scarlatinosa |
Dundee cardiovascular risk score |
Dundee Coronary Risk Disk (assessment scale) |
Duodenitis caused by ingestible alcohol |
Duodenitis caused by ethanol (disorder) |
Duodenoscopy: [diagnostic NOS] or [NEC] |
Duodenoscopy |
Duplicate concept |
Duplicate component (foundation metadata concept) |
Duplicate report |
Duplicate report (record artifact) |
Dupuytren contracture repaired by division of palmar aponeurosis |
Dupuytren contracture corrected by division of palmar aponeurosis |
Dupuytren's disease of finger(s), nodules with no contracture |
Dupuytren's disease of finger |
Dupuytren's disease of palm, nodules with no contracture |
Dupuytren's disease of palm |
Dyclonine hydrochloride 1% topical solution (product) |
Product containing precisely dyclonine hydrochloride 10 milligram/1 milliliter conventional release cutaneous solution (clinical drug) |
Dynamite, device |
Dynamite stick (physical object) |
Dyphylline + guaifenesin 100mg/100mg elixir |
Product containing precisely diprophylline 6.67 milligram/1 milliliter and guaifenesin 6.67 milligram/1 milliliter conventional release oral solution (clinical drug) |
Dyphylline 160mg/15ml elixir |
Diprophylline 10.7 mg/mL oral solution |
Dyskinesia of esophagus |
Diffuse spasm of esophagus |
Dysmnesic seizure |
Focal onset cognitive epileptic seizure with memory impairment |
Dyssegmental dysplasia with glaucoma syndrome |
Rolland-Debuqois syndrome |
Dyssocial behavior of child or adolescent |
Dyssocial behavior of child or adolescent (finding) |
Dysthyroid ophthalmopathy |
Exophthalmos due to thyroid eye disease (disorder) |
E-mail report |
Email report (record artifact) |
ECG equivocal |
ECG equivocal |
ECG: left ventricular strain |
ECG: left ventricular strain |
ERCP &/or Endoscopic sphincterotomy of sphincter of Oddi and removal of calculus |
ERCP (endoscopic retrograde cholangiopancreatography) sphincterotomy of sphincter of Oddi and calculus removal |
Ear flap |
Flap (substance) |
Ear sign or symptom |
Ear and auditory finding (finding) |
Ear/nose/throat symptom NOS |
Ear, nose and throat finding |
Ear/nose/throat symptom NOS |
Ear, nose and throat finding |
Ear/nose/throat symptoms NOS |
Ear, nose and throat finding |
Ear/nose/throat symptoms NOS |
Ear, nose and throat finding |
Early onset pauciarticular chronic arthritis |
Juvenile idiopathic arthritis, oligoarthritis (disorder) |
Early operation NOC NOS |
Surgical procedure (procedure) |
Early operation NOC OS |
Surgical procedure (procedure) |
Early operations NOC |
Surgical procedure (procedure) |
Ebola virus |
Genus Ebolavirus (organism) |
Ebola virus Ivory Coast subtype |
Ivory Coast ebolavirus (organism) |
Ebola virus Reston biotype |
Reston ebolavirus (organism) |
Ebola virus Sudan biotype |
Sudan ebolavirus (organism) |
Ebola virus Zaire biotype |
Zaire virus (organism) |
Ebola virus disease |
Ebola virus disease |
Eccrine papillary adenocarcinoma |
Digital papillary adenocarcinoma |
Echinococcus granulosus infection of other site |
Echinococcus granulosus infection |
Echinococcus multilocularis infection of other site |
Echinococcus multilocularis infection |
Echinocyte |
Burr cell |
Echothiophate iodide 0.03% eye drops |
Ecothiopate iodide 300 microgram/mL eye solution |
Echothiophate iodide 0.06% eye drops |
Product containing precisely ecothiopate iodide 600 microgram/1 milliliter conventional release eye solution (clinical drug) |
Echothiophate iodide 0.125% solution |
Ecothiopate (as ecothiopate iodide) 1.25 mg/mL eye solution |
Echothiophate iodide 0.25% eye drops |
Ecothiopate iodide 2.5 mg/mL eye solution |
Econazole nitrate 150mg/1% pessaries+cream |
Econazole only product |
Ecothiopate iodide 0.125% eye drops |
Ecothiopate iodide 1.25 mg/mL eye solution |
Ectopic hormone secretion, NEC |
Ectopic production of endocrine substance |
Eczema of leg |
Eczema of lower limb |
Edetate disodium 150mg/mL injection solution ampule |
Edetate disodium 150 mg/mL solution for injection |
Education about microenterprise development organization |
Education about microenterprise development program |
Educational (& school) problem or difficulties |
Education and/or schooling finding |
Educational status |
Educational achievement |
Educational therapy |
Educational therapy |
Edwardsiella anguillimortifera |
Edwardsiella tarda |
Eel - dietary |
Eel (substance) |
Eflornithine hydrochloride 13.9% cream |
Eflornithine (as eflornithine hydrochloride) 139 mg/mL cutaneous cream |
Eflornithine hydrochloride 139mg/g cream |
Eflornithine (as eflornithine hydrochloride) 139 mg/mL cutaneous cream |
EgAn1824-61 virus |
EgAN 1825-61 virus (organism) |
Egyptian goose breed (organism) |
Alopochen aegyptiacus |
Ehlers-Danlos syndrome vascular-like type |
Ehlers-Danlos syndrome classic type (disorder) |
Ehlers-Danlos syndrome with periventricular heterotopia |
Periventricular nodular heterotopia |
Ehlers-Danlos syndrome, dominant type 4 |
Vascular Ehlers-Danlos syndrome |